Opinion

Video

Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

Author(s):

Bradley Monk, MD,Dana M. Chase, MD, FACOG

Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer and at least one prior line of therapy, and the management of toxicities such as neuropathy and pneumonitis.

Related Videos
4 experts are featured in this series.
Related Content
Endometrial Cancer | Image Credit: © Dr_Microbe - stock.adobe.com
January 20th 2025

European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Rebecca Arend, MD
January 8th 2025

Multidisciplinary Collaboration Is Crucial in Managing Ocular Toxicities of Mirvetuximab Soravtansine in Gynecologic Tumors

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center
December 28th 2024

Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care